![](https://endpts.com/wp-content/uploads/2023/11/Doug-Drysdale-Cybin-tile.jpg)
Doug Drysdale, Cybin CEO
Cybin gears up for registrational trial of psilocybin analog in major depression after PhII success
Cybin’s psychedelic-inspired drug candidate has met the primary endpoint of its mid-stage test in major depressive disorder (MDD), sparking preparations for a Phase III trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.